Open AccessEfficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
Author(s) -
Kume Shinji,
Uzu Takashi,
Takagi Chieko,
Kondo Morihiro,
Okabe Tomoko,
Araki Shinichi,
Isshiki Keiji,
Takeda Naoko,
Kondo Keiko,
Haneda Masakazu,
Koya Daisuke,
Nishio Yoshihiko,
Kashiwagi Atsunori,
Maegawa Hiroshi
Publication year - 2012
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/j.2040-1124.2011.00169.x
Subject(s) - medicine , vildagliptin , tolerability , postprandial , type 2 diabetes , hypoglycemia , glycemic , diabetes mellitus , hemodialysis , adverse effect , linagliptin , gastroenterology , endocrinology , insulin
Anti‐diabetic agent‐related hypoglycemia is a serious complication in type 2 diabetic patients on hemodialysis. Therefore, we assessed the efficacy and tolerability of 24 weeks of monotherapy with vildagliptin, a dipeptidyl peptidase four inhibitor, which is a new class of antidiabetic agent. This open‐label, single‐arm clinical trial was performed on 26 patients on hemodialysis. The primary assessments were changes in postprandial glucose level and glycated albumin (GA). During the study, three patients dropped out, and data from 23 patients were analyzed. Significant reductions were seen in postprandial glucose (−2.60 ± 3.80 mmol/L, P < 0.001) and GA (−2.59 ± 2.33%, P < 0.001) levels. No serious drug‐related adverse events were observed. Vildagliptin monotherapy can be recommended for glycemic control in type 2 diabetic patients on hemodialysis. This trial was registered with the University Hospital Medical Information Network (no. UMIN3661). (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00169.x, 2011)